Giuseppe Rossi

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 726 citations · Full text

Medicine, Hematology, Oncology +12

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial

Andrés JM Ferreri, Michele Reni, Marco Foppoli et al. · The Lancet · 2009 · 662 citations · Full text

Medicine, Oncology, Pharmacology +10

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

Renato Bassan, Orietta Spinelli, Elena Oldani et al. · Blood · 2009 · 430 citations · Full text

Medicine, Oncology, Chemotherapy +13

A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy

Alessandra Tucci, Samantha Ferrari, Chiara Bottelli et al. · Cancer · 2009 · 281 citations

Medicine, Geriatric Medicine, Oncology +17

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Lydia Scarfò, Thomas Chatzikonstantinou, Gian Matteo Rigolin et al. · Leukemia · 2020 · 275 citations · Full text

Medicine, Hematology, Internal Medicine +10